InMed Pharmaceuticals and the Almac Group have partnered on a proprietary approach to augment current biosynthesis-based methods for cannabinoid production.
Almac Group, the global contract development and manufacturing organisation, is delighted to announce the successful MHRA registration of its High Throughput GMP Peptide manufacturing facility.